

Piera Gargiulo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6620090/publications.pdf>

Version: 2024-02-01

15
papers

472
citations

1040056

9
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

1238
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. <i>Cancer Treatment Reviews</i> , 2016, 48, 61-68.	7.7	102
2	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIDVID-19 prospective trial. <i>Journal of Translational Medicine</i> , 2020, 18, 405.	4.4	98
3	Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy. <i>Cancer Treatment Reviews</i> , 2015, 41, 136-143.	7.7	76
4	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. <i>Breast</i> , 2017, 31, 114-120.	2.2	49
5	Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. <i>BMC Cancer</i> , 2016, 16, 375.	2.6	31
6	Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. <i>Gynecologic Oncology</i> , 2017, 144, 72-76.	1.4	28
7	Phase I trial of the oral smoothed inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 766-772.	2.6	25
8	Long-Term Toxicity and Quality of Life in Patients Treated for Locally Advanced Cervical Cancer. <i>Oncology</i> , 2016, 90, 29-35.	1.9	17
9	Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591881835.	3.2	13
10	Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. <i>Cells</i> , 2020, 9, 903.	4.1	8
11	Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08). <i>British Journal of Cancer</i> , 2019, 120, 968-974.	6.4	7
12	Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study. <i>Cancers</i> , 2021, 13, 5152.	3.7	7
13	The Use of Not-Negative Conclusions to Describe Results of Formally Negative Trials Presented at Oncology Meetings. <i>JAMA Oncology</i> , 2020, 6, 926.	7.1	5
14	Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/ManGO-OV2 Advanced Ovarian Cancer Patients. <i>Cancers</i> , 2022, 14, 1849.	3.7	3
15	Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. <i>Tumori</i> , 2013, 99, e131-e133.	1.1	2